Drugs / EB-NK-301
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07589530 | Mar 2026 → Feb 2027 expected | metastatic malignant neoplasm | Beijing Biotech | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EB-NK-301 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07589530 ↗ |
| Modality | Cell therapy | “investigational off-the-shelf allogeneic CAR-NK cell product targeting TROP2” NCT07589530 ↗ |
| Route | Intravenous | “administered by intravenous infusion.” NCT07589530 ↗ |